Montreal, Canada, March 14, 2013 – MethylGene Inc. (“MethylGene” or the “Company”) (TSX: MYG) today announced that Messrs. Jeffrey M. Besterman, PhD, Executive Vice President Research and Development and Chief Scientific Officer, Joe Walewicz, Vice President of Business and Corporate Development and Klaus B. Kepper, Vice President Finance and Chief Financial Officer, will be leaving the company to pursue other interests.
Effective immediately, the responsibilities of Dr. Besterman have been assumed by Charles Baum, MD PhD, CEO, and the responsibilities of Mr. Kepper and Mr. Walewicz have been assumed by Mark Gergen, COO. Each of the executives will depart following a brief transition period.
“I want to personally thank Klaus, Jeff and Joe for their contributions to MethylGene” said Dr. Charles Baum, President and CEO, “we wish them the best in their future pursuits”.
MethylGene Inc. (TSX:MYG) is a drug development company that is advancing novel therapeutics for cancer and infectious disease in human clinical trials. The Company’s lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is in a Phase II trial for vulvovaginal candidiasis, and MGCD265, a multi-targeted receptor tyrosine kinase inhibitor that is in Phase I/II clinical trials for patients with solid tumors. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.